GLP & Metabolic Research

Retatrutide is a synthetic 39-residue fatty-acid-conjugated peptide acting as a triple agonist at the GIP, GLP-1 and glucagon receptors. The added glucagon receptor activity is what distinguishes it from dual agonists such as tirzepatide, and it appears frequently in comparative metabolic-pharmacology literature.

This vial contains 5mg of lyophilized powder, equivalent to approximately 1.06 µmol.

• Vial contents: 5mg lyophilized powder (batch RET-5-260801-L001 tested at 5.86mg)
• Molar content: approximately 1.06 µmol per vial (based on labeled mass)
• Molecular weight: 4731.33 g/mol
• Classification: Triple GIP / GLP-1 / glucagon receptor agonist
• Sequence: 39-residue modified backbone with fatty-acid conjugate for albumin binding
• Purity: 99.636% by RP-HPLC (batch RET-5-260801-L001) — see COA

For laboratory research use only. Not for human or veterinary use.

Tirzepatide is a synthetic 39-residue peptide carrying a C20 fatty diacid chain that acts as a dual agonist at both the GIP and GLP-1 receptors. It is among the most widely referenced compounds in current incretin and metabolic-signalling literature, and is frequently used as a comparator in receptor-selectivity studies.

This vial contains 60mg of lyophilized powder, equivalent to approximately 12.47 µmol.

• Vial contents: 60mg lyophilized powder (batch TIR-60-260801-L001 tested at 66.09mg)
• Molar content: approximately 12.47 µmol per vial (based on labeled mass)
• Molecular weight: 4813.45 g/mol
• Classification: Dual GIP / GLP-1 receptor agonist
• Sequence: 39-residue modified backbone based on the native GIP sequence, with a C20 diacid linked at Lys20 for albumin binding
• Purity: 99.658% by RP-HPLC (batch TIR-60-260801-L001) — see COA

For laboratory research use only. Not for human or veterinary use.